antiplatelet therapy as appropriate duration) study Masato Nakamura, - - PowerPoint PPT Presentation

▶
antiplatelet therapy as appropriate duration study
SMART_READER_LITE
LIVE PREVIEW

antiplatelet therapy as appropriate duration) study Masato Nakamura, - - PowerPoint PPT Presentation

Sep 03, 2023 166 likes •272 views

The long-term follow-up of patients in the NIPPON (Nobori dual antiplatelet therapy as appropriate duration) study Masato Nakamura, MD. Phd. Disclosures Grants from Terumo corp. Daiichi Sankyo and Sanofi KK outside the submitted work

slide-1
SLIDE 1

The long-term follow-up of patients in the NIPPON (Nobori dual antiplatelet therapy as appropriate duration) study Masato Nakamura, MD. Phd.

Disclosures Grants from Terumo corp. Daiichi Sankyo and Sanofi KK outside the submitted work Honoraria from Terumo corp. Daiichi Sankyo KK, Astra-Zeneka KK, and Sanofi KK

slide-2
SLIDE 2
slide-3
SLIDE 3

Background

  • NIPPON study demonstrated the non-inferiority of 6

months dual antiplatelet therapy (DAPT) in terms of NACCE compared with 18 months DAPT after drug- eluting stent (DES) deployment

(J Am Coll Cardiol Interv 2017; 10:1189-98).

  • Many previous trials comparing different durations of

DAPT after DES implantation had short observation periods and lower than anticipated event rates.

slide-4
SLIDE 4
  • The 3-year data of the present study might provide

additional insight into the risks and benefits of short- term DAPT.

  • Deciding the balance between risks and benefits is

not easy and consensus criteria for individualizing the duration of DAPT have not been established.

  • CART analysis may provide some assistance when

selecting the optimal duration of DAPT.

slide-5
SLIDE 5

Purpose

  • To assess the long-term efficacy and safety of short-term DAPT by analysis of 3-year follow-

up data. Key point about methods

  • A total of 3773 patients was randomized to 2 groups (6 month DAPT vs 18 months DAPT)
  • Kaplan-Meier analysis was performed to estimate the probability of the occurrence of

event at 3 year.

– NACCE (all-cause mortality, myocardial infarction, stroke, or major bleeding) – Efficacy end point (cardiac death, myocardial infarction, stroke, and definite or probable stent thrombosis) – Safety end point (BARC2, 3 or 5 bleeding)

  • CART analysis was conducted to define the subgroup benefitting from long-term DAPT
slide-6
SLIDE 6

NACCE: death, MI, Stroke, major bleeding

0 6 9 12 18 24 36 Months since Enrollment 2 4 6 8 10 Cumulative Incidence (%) 1653 1541 1488 1266 887 214 1654 1499 1426 1230 839 172

  • No. at Risk

Long-term DAPT Short-term DAPT

HR: 1.49 (95%CI: 0.97, 2.27) Log-rank p=0.06 Long-term DAPT Short-term DAPT

3 6 9 12 18 24 36 Months since Enrollment 2 4 6 8 10 Cumulative Incidence (%) 1887 1646 1466 1213 878 210 1886 1684 1410 1216 833 169

  • No. at Risk

Long-term DAPT Short-term DAPT

HR: 1.20 (95%CI: 0.87, 1.66) Log-rank p=0.27 Long-term DAPT Short-term DAPT

4.85% 7.03% 3.48% 5.60%

slide-7
SLIDE 7

Efficacy end point CV death, MI, stroke, ST

6 9 12 18 24 36 Months since Enrollment 2 4 6 8 10 Cumulative Incidence (%)

1653 1469 1271 937 212 1654 1425 1233 909 173

  • No. at Risk

Long-term DAPT Short-term DAPT

HR: 1.02 (95%CI: 0.59, 1.78) Log-rank p=0.94 Long-term DAPT Short-term DAPT 0 6 9 12 18 24 36 Months since Enrollment 2 4 6 8 10 Cumulative Incidence (%)

1653 1527 1279 889 214 1654 1490 1245 845 173

  • No. at Risk

Long-term DAPT Short-term DAPT

HR: 1.53 (95%CI: 0.81, 2.87) Log-rank p=0.17 Long-term DAPT Short-term DAPT

Safety end point BARC 2,3, or 5

Landmark analysis (6M-3 year)

2.58% 1.70% 2.22% 2.01%

slide-8
SLIDE 8

Long-term DAPT 1.0%(16/1653) Short-term DAPT 1.5%(24/1654) Log-rank p= HR (95%CI): 1.53 (0.81, 2.87) Long-term DAPT 0.5%(4/854) Short-term DAPT 0.5%(4/863) Log-rank p=0.96 HR (95%CI): 1.04 (0.26, 4.15)

<70

Long-term DAPT 1.5%(12/790) Short-term DAPT 2.6%(20/778) Log-rank p=0.14 HR (95%CI): 1.68 (0.82, 3.44) age

>70

Long-term DAPT 1.5%(10/671) Short-term DAPT 1.8%(12/652) Log-rank p=0.64 HR (95%CI): 1.21 (0.52, 2.81)

<23.3

Long-term DAPT 0.0%(0/26) Short-term DAPT 18.8%(6/32) Log-rank p=0.01 HR (95%CI): 13.24 (0.59, 298.17) Syntax Score

>23.3

Long-term DAPT 1.8%(10/561) Short-term DAPT 2.3%(12/534) Log-rank p=0.59 HR (95%CI): 1.25 (0.54, 2.90)

<81.429

Long-term DAPT 0.0%(0/88) Short-term DAPT 0.0%(0/98) eGFR

>81.429

Long-term DAPT 1.0%(16/1653) Short-term DAPT 1.5%(24/1654) Log-rank p= HR (95%CI): 1.53 (0.81, 2.87) Long-term DAPT 0.5%(4/854) Short-term DAPT 0.5%(4/863) Log-rank p=0.96 HR (95%CI): 1.06 (0.21, 5.26)

<70

Long-term DAPT 1.5%(12/790) Short-term DAPT 2.6%(20/778) Log-rank p=0.14 HR (95%CI): 1.68 (0.82, 3.44) age

>70

Long-term DAPT 1.8%(9/494) Short-term DAPT 3.5%(17/489) Log-rank p=0.10 HR (95%CI): 1.89 (0.84, 4.23)

<77

Long-term DAPT 1.0%(3/296) Short-term DAPT 1.0%(3/289) Log-rank p=0.94 HR (95%CI): 1.06 (0.21, 5.26) Age

>77

Long-term DAPT 1.7%(5/292) Short-term DAPT 2.0%(6/307) Log-rank p=0.81 HR (95%CI): 1.14 (0.35, 3.74)

NO

Long-term DAPT 2.0%(4/202) Short-term DAPT 6.0%(11/182) Log-rank p=0.04 HR (95%CI): 2.89 (0.94, 8.91) DM

YES

slide-9
SLIDE 9

Conclusions

  • Short-term and long-term DAPT showed no

significant difference of net clinical benefit up to 3 years after drug-eluting stent implantation.

  • However, patients with a higher event risk

may be candidates for long-term DAPT.